BioCentury
ARTICLE | Clinical News

AbbVie's Rova-T suffers another setback in SCLC

December 7, 2018 1:28 AM UTC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product led to a lower improvement on the primary endpoint of overall survival (OS) vs. topotecan.

The failure is the second setback this year for the product, which was the centerpiece of AbbVie's 2016 acquisition of Stemcentrx Inc. for $5.8 billion up front and up to $4 billion in milestones...